Abstract:Introduction The ongoing donor kidney shortage has necessitated the increasing use of higher Kidney Donor Profile Index (KDPI) kidneys. Our aim was to investigate machine perfusion (MP) as a strategy to optimise outcomes from these grafts, in particular through the pharmacologic targeting of ischaemia-reperfusion injury (IRI). Materials/Methods (i) A systematic review/meta-analysis was conducted to compare renal transplantation outcomes after hypothermic (HMP) and normothermic (NMP) MP in comparison to static cold storage (CS) using both clinical and experimental data, and thence identify areas for further investigation using animal experimental models. (ii) Directed drug delivery to the kidney, delivered using MP and targeting IRI, was identified as an important area for further research. Three different IRI targets (CD47 antibody, soluble complement receptor 1 [sCR1], and recombinant thrombomodulin [rTM]), delivered intra-renally, were therefore compared in a rodent model of kidney IRI. (iii) NMP was identified as a promising preservation modality for further clinical implementation; therefore a NMP system was developed/optimised using a porcine donation after cirulatory death (DCD) model. The impact of CD47 and sCR1 on NMP parameters was subsequently investigated. Results (i) Hypothermic MP (HMP) reduces kidney delayed graft function in comparison to CS (RR 0.77, 95% CI 0.69 to 0.87), but there is no cumulative study evidence for an improvement in longer-term outcomes. NMP evidence is largely limited to the experimental setting and indicates that NMP is superior to HMP with regards to subsequent renal function (mean difference of peak creatinine -1.66; 95% CI -3.19 to -0.14). Drug delivery targeting IRI is under-explored in MP studies. (ii) A rodent renal IRI model was established, and preliminary evidence (day 1 and 7 renal function and histopathology) indicates intra-renal delivery of CD47 and/or soluble complement receptor 1 may ameliorate IRI. (iii) A clinically translatable NMP system was developed and tested using a porcine kidney donation after circulatory death model. Pressure-controlled perfusion, using a leukocyte-depleted, colloid-containing perfusate produced ideal baseline conditions. Addition of CD47 to the perfusion circuit impacts on perfusion and biochemical parameters, including intra-renal resistance, urine output, and creatinine clearance. Discussion Renal HMP does not seem to modulate longer-term graft outcomes. IRI of the kidney can be ameliorated by the intra-renal delivery of pharmocotherapies such as CD47 blocking antibody. NMP presents the ideal opportunity to deliver such IRI-targeting drugs to the kidney and simultaneously assess kidney function and may enhance the impact of this preservation modality. Conclusion Modification of perfusion conditions using NMP in combination with drug(s) targeting IRI may further improve transplantation outcomes, and avoids systemic treatment of the donor or recipient.

The Dual-specificity Phosphatase 3 (DUSP3): A Potential Target Against Renal Ischemia/Reperfusion Injury

Dual-specificity Phosphatase 26 Protects Against Kidney Injury Caused by Ischaemia-Reperfusion Through Restraint of TAK1-JNK/p38-mediated Apoptosis and Inflammation of Renal Tubular Epithelial Cells

DUSP1 Alleviates Cardiac Ischemia/reperfusion Injury by Suppressing the Mff-required Mitochondrial Fission and Bnip3-related Mitophagy Via the JNK Pathways

Pharmacological Inhibition Of Myd88 Homodimerization Counteracts Renal Ischemia Reperfusion-Induced Progressive Renal Injury In Vivo And In Vitro

SIRT3 Protects Kidneys from Ischemia-Reperfusion Injury by Modulating the DRP1 Pathway to Induce Mitochondrial Autophagy

DUSP12 ameliorates myocardial ischemia–reperfusion injury through HSPB8‐induced mitophagy

Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform

Dl-3-n-butylphthalide pretreatment attenuates renal ischemia/reperfusion injury

Usp49 Inhibits Ischemia-Reperfusion-Induced Cell Viability Suppression And Apoptosis In Human Ac16 Cardiomyocytes Through Dusp1-Jnk1/2 Signaling

DUSP5 deficiency suppresses the progression of acute kidney injury by enhancing autophagy through AMPK/ULK1 pathway

NLRP3 inflammasome: A potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation

Intra-Renal Delivery of Drugs Targeting Ischemia-Reperfusion Injury of the Kidney using Normothermic Machine Perfusion

Delayed Ischemic Preconditioning Attenuated Renal Ischemia-Reperfusion Injury by Inhibiting Dendritic Cell Maturation

Transcriptomic Analysis Revealed an Important Role of Peroxisome-Proliferator-Activated Receptor Alpha Signaling in Src Homology Region 2 Domain-Containing Phosphatase-1 Insufficiency Leading to the Development of Renal Ischemia-Reperfusion Injury

Ischemic Preconditioning Alleviates Mouse Renal Ischemia/Reperfusion Injury by Enhancing Autophagy Activity of Proximal Tubular Cells

Dusp14 protects against hepatic ischaemia-reperfusion injury via Tak1 suppression.

Mechanisms and Potential Therapeutic Targets

Dual-specificity phosphatase 1 interacts with prohibitin 2 to improve mitochondrial quality control against type-3 cardiorenal syndrome

Protective effects and mechanisms of dapagliflozin on renal ischemia/reperfusion injury

Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury

Renal Ischemia/reperfusion-Induced Mitophagy Protects Against Renal Dysfunction Via Drp1-dependent-pathway